BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 3 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,916 | -80.7% | 4,508 | -80.8% | 0.00% | -83.3% |
| Q2 2023 | $165,594 | +168873.5% | 23,522 | +99.4% | 0.01% | +100.0% |
| Q1 2023 | $98 | -47.3% | 11,799 | -27.3% | 0.00% | -62.5% |
| Q4 2022 | $186 | -100.0% | 16,226 | -65.3% | 0.01% | -20.0% |
| Q3 2022 | $589,000 | +55.0% | 46,713 | +30.3% | 0.01% | +11.1% |
| Q2 2022 | $380,000 | +44.5% | 35,861 | +121.6% | 0.01% | +200.0% |
| Q1 2022 | $263,000 | -23.5% | 16,180 | -34.8% | 0.00% | -50.0% |
| Q4 2021 | $344,000 | -38.5% | 24,829 | -36.1% | 0.01% | -57.1% |
| Q3 2021 | $559,000 | +81.5% | 38,885 | +99.7% | 0.01% | +75.0% |
| Q2 2021 | $308,000 | -50.5% | 19,472 | -68.1% | 0.01% | -20.0% |
| Q1 2021 | $622,000 | +30.9% | 61,104 | -4.3% | 0.01% | -33.3% |
| Q4 2020 | $475,000 | -68.8% | 63,838 | -85.6% | 0.02% | -11.8% |
| Q3 2020 | $1,524,000 | +218.2% | 443,635 | +341.5% | 0.02% | -15.0% |
| Q2 2020 | $479,000 | +15866.7% | 100,491 | +28367.7% | 0.02% | – |
| Q1 2019 | $3,000 | +200.0% | 353 | +16.1% | 0.00% | – |
| Q4 2017 | $1,000 | -98.0% | 304 | -96.8% | 0.00% | -100.0% |
| Q3 2017 | $50,000 | +1566.7% | 9,439 | +1473.2% | 0.00% | – |
| Q2 2017 | $3,000 | -93.3% | 600 | -91.7% | 0.00% | -100.0% |
| Q4 2016 | $45,000 | +2150.0% | 7,239 | +1512.2% | 0.01% | – |
| Q3 2016 | $2,000 | -71.4% | 449 | -81.4% | 0.00% | -100.0% |
| Q2 2016 | $7,000 | -84.1% | 2,417 | -43.0% | 0.00% | -85.7% |
| Q4 2015 | $44,000 | -37.1% | 4,237 | -9.3% | 0.01% | +16.7% |
| Q2 2015 | $70,000 | -1.4% | 4,673 | -40.1% | 0.01% | -33.3% |
| Q1 2015 | $71,000 | +129.0% | 7,802 | +202.3% | 0.01% | +200.0% |
| Q4 2014 | $31,000 | +72.2% | 2,581 | +40.3% | 0.00% | +50.0% |
| Q3 2014 | $18,000 | -91.3% | 1,839 | -88.6% | 0.00% | -92.6% |
| Q2 2014 | $207,000 | +1492.3% | 16,161 | +1211.8% | 0.03% | +1250.0% |
| Q1 2014 | $13,000 | +116.7% | 1,232 | +60.4% | 0.00% | +100.0% |
| Q4 2013 | $6,000 | -94.7% | 768 | -95.1% | 0.00% | -91.7% |
| Q3 2013 | $114,000 | +533.3% | 15,628 | +34.9% | 0.01% | +1100.0% |
| Q2 2013 | $18,000 | – | 11,582 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |